Aberrant activity of mTOR signaling has been demonstrated in many NDs, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and PrDs (41, 42), and the central role of mTOR activity together with the availability of approved mTOR inhibitors, such as rapamycin and derivatives, has made it an attractive drug target in the search for a treatment for neurodegeneration. This evidence concerns the gene MTOR and Parkinson disease.